Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nailner 2 in 1 as Adjuvant to Ciclopirox in Onychomycosis
NCT02961634Phase 3Unknown
- Start
- Apr 2017
- Primary completion
- Aug 2017
01
Overview
Phase 3, randomised, single-blind trial (2 arms). Primary endpoint: Percent of improvement of mycosis by reducing the area of the lesion at 90 days. Status: unknown.
Beyond the preview
Go deeper on NCT02961634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961634.